4.7 Article

Prevalence, Treatment, and Control Rates of Conventional and Ambulatory Hypertension Across 10 Populations in 3 Continents

Journal

HYPERTENSION
Volume 70, Issue 1, Pages 50-58

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/HYPERTENSIONAHA.117.09188

Keywords

blood pressure; diabetes mellitus; hypertension; prevalence; special populations

Funding

  1. National Institute of Aging [1-R01AG036469 A1]
  2. Fogarty International Center
  3. FONACIT [G-97000726]
  4. FundaConCiencia [LOCTI/008-2008]
  5. European Union [IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093, HEALTH-F4-2007-201550, HEALTH-F7-249-EU MASCARA, HEALTH-F7-305507-HOMAGE]
  6. European Union (European Research Council) [294713]
  7. Fonds voor Wetenschappelijk Onderzoek Vlaanderen
  8. Ministry of the Flemish Community, Brussels, Belgium [G.0734.09, G.0881.13, G.0880.13N]
  9. Ministry of Education, Culture, Sports, Science, and Technology, Japan [23249036, 23390171, 24390084, 24591060, 24790654, 25253059, 25461083, 25461205, 25860156, 26282200, 26860093, 16H05243, 16K09472, 16K11850, 16K15359]
  10. Japan Society for the Promotion of Science (JSPS) [25*7756, 25*9328, 26*857, 27*656]
  11. Japan Arteriosclerosis Prevention Fund
  12. Intramural Research Fund for Cardiovascular Diseases of National Cerebral and Cardiovascular Center [22-4-5]
  13. Health Labor Sciences Research Grant from Ministry of Health, Labor, and Welfare, Japan [H26-Junkankitou [Seisaku]-Ippan-001]
  14. Asociacion Espanola Primera en Salud (AEPS)
  15. Danish Heart Foundation [01-2-9-9A-22914]
  16. Lundbeck Fonden [R32-A2740]
  17. National Natural Science Foundation of China [81170245, 81270373, 81470533, 91639203]
  18. Ministry of Science and Technology, Beijing, China [2013CB530700]
  19. Ministry of Science and Technology (grant for China-European Union collaborations), Beijing, China [1012]
  20. Shanghai Commissions of Science and Technology [14ZR1436200, 15XD1503200]
  21. Education (Gaofeng Clinical Medicine Grant) [20152503]
  22. Charles University Research Fund [P36]
  23. Grants-in-Aid for Scientific Research [16K15359] Funding Source: KAKEN
  24. European Research Council (ERC) [294713] Funding Source: European Research Council (ERC)
  25. Steno Diabetes Center Copenhagen (SDCC) [SDCC 3.A Complications] Funding Source: researchfish

Ask authors/readers for more resources

Hypertension is a major global health problem, but prevalence rates vary widely among regions. To determine prevalence, treatment, and control rates of hypertension, we measured conventional blood pressure (BP) and 24-hour ambulatory BP in 6546 subjects, aged 40 to 79 years, recruited from 10 community-dwelling cohorts on 3 continents. We determined how between-cohort differences in risk factors and socioeconomic factors influence hypertension rates. The overall prevalence was 49.3% (range between cohorts, 40.0%-86.8%) for conventional hypertension (conventional BP >= 140/90 mm Hg) and 48.7% (35.2%-66.5%) for ambulatory hypertension (ambulatory BP >= 130/80 mm Hg). Treatment and control rates for conventional hypertension were 48.0% (33.5%-74.1%) and 38.6% (10.1%-55.3%) respectively. The corresponding rates for ambulatory hypertension were 48.6% (30.5%-71.9%) and 45.6% (18.6%-64.2%). Among 1677 untreated subjects with conventional hypertension, 35.7% had white coat hypertension (23.5%-56.2%). Masked hypertension (conventional BP < 140/90 mm Hg and ambulatory BP >= 130/80 mm Hg) occurred in 16.9% (8.8%-30.5%) of 3320 untreated subjects who were normotensive on conventional measurement. Exclusion of participants with diabetes mellitus, obesity, hypercholesterolemia, or history of cardiovascular complications resulted in a <9% reduction in the conventional and 24-hour ambulatory hypertension rates. Higher social and economic development, measured by the Human Development Index, was associated with lower rates of conventional and ambulatory hypertension. In conclusion, high rates of hypertension in all cohorts examined demonstrate the need for improvements in prevention, treatment, and control. Strategies for the management of hypertension should continue to not only focus on preventable and modifiable risk factors but also consider societal issues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available